NICE data highlight hypertension management needs:
This article was originally published in Clinica
Updated guidance on the management of hypertension, issued by the UK's National Institute for Health and Clinical Excellence (NICE) today (June 28), focuses on the pharmacological treatment of the condition, adding nothing new to current policy on diagnosis and monitoring. However, data on the UK's incidence of the condition reveal that around 40% of the adult population are hypertensive - the proportion rises with age - and that inadequate management of the condition is the single greatest risk factor in stroke, coronary heart disease and chronic renal failure.
You may also be interested in...
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.